CA-CLOUDBLUE
CloudBlue, a leading cloud ecosystem technology company, has completed the acquisition and integration of Harmony Business Systems (HBS). Its comprehensive professional services automation (PSA) and revenue management software is now a complement to CloudBlue’s portfolio of services designed to simplify and accelerate resellers’ transition to an everything-as-a-service business.
As a CloudBlue company, UK-based HBS will independently operate HarmonyPSA, to serve customers around the world. Launched over a decade ago and with customers in 15 countries, the platform features multi-language support and enjoys one of the highest customer satisfaction ratings in the industry. It was purpose-built to manage any type of service by unifying sales, operations and finance functions. HarmonyPSA combines CRM, ticketing, storefront, lead generation, assisted sales, and vendor competency and incentive programs into a single solution as a quote to cash and accounting system. It is now available for the first time on the UK Ingram Micro Cloud Marketplace.
Resellers will have a dedicated instance to quickly find and procure hardware and software, pay-as-you-go and recurring subscription cloud technologies across various online marketplaces, including Ingram Micro Online and Ingram Micro Cloud Marketplace. HarmonyPSA automates the billing process and provides accurate, real-time views of customers’ contracts, projects and profitability.
“The acquisition of Harmony is a direct response to our MSP partners’ requests to help them quickly transform and grow a cloud services business with less risk,” said Nimesh Davé, president of CloudBlue and Ingram Micro Cloud. “We are delighted to have the Harmony team join our CloudBlue community as we expand our technology offerings.”
“We’re extremely excited to join the CloudBlue family to capitalize on our shared commitment of driving growth for our customers,” said Steve Powell, co-founder and CTO of Harmony Business Systems. “By working together, we will dramatically scale our customer base and expand our offering across various marketplaces.”
Stephen Robitaille, director of sales operations at intlx Solutions and a customer of HarmonyPSA, is enthusiastic about the platform's ability to automatically create purchase orders and generate unique reports that track project profitability on all aspects of the business. "It's made my work much easier and our business much more efficient."
More information on HarmonyPSA and how it helps accelerate the digital transformation of reseller partners is available at www.harmonypsa.com .
About CloudBlue
CloudBlue provides a hyperscale platform with hypergrowth products and services that allows providers to launch and manage an omni-product, multi-tier and multi-channel marketplace. With CloudBlue, providers can access and capitalize on a hyperconnected ecosystem of 200+ top-selling vendors, 200+ leading brands and more than 80,000 partners globally. Many of the world’s best-known software and SaaS vendors, digital service providers, technology distributors, tech manufacturers, managed services providers and value-added resellers rely on CloudBlue’s leading CloudBlue Commerce and CloudBlue Connect platforms to automate, aggregate and sell both their own cloud services as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions. More at www.cloudblue.com .
About Harmony Business Systems
Harmony Business Systems Ltd., a CloudBlue company, is the company behind HarmonyPSA, the most complete cloud professional services automation (PSA) software on the market. Purpose-built with functionality to cater to even the most complex needs of MSPs, VARs, ISVs and Professional Services Organizations, HarmonyPSA truly is the next-generation PSA system built for today’s Modern Service Provider. Amplified by CloudBlue’s powerful cloud services automation platform, HarmonyPSA empowers services organizations to scale recurring channel revenue and diminish operational complexity via its advanced product suite, which includes automated billing and reconciliation, real-time profitability analysis, an industry-leading customer support center and network operations center (NOC), and much more. To learn more, visit www.harmonypsa.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom